Valsartan Losartan And Irbesartan | Honik Law
16000
post-template-default,single,single-post,postid-16000,single-format-standard,bridge-core-2.8.5,qode-page-transition-enabled,ajax_fade,page_not_loaded,,side_area_uncovered_from_content,qode-child-theme-ver-1.0.0,qode-theme-ver-26.9,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.6.0,vc_responsive
 

Valsartan, Losartan and Irbesartan Recalls

Valsartan, Losartan and Irbesartan Recalls

Valsartan, losartan, and irbesartan are popular generic drugs primarily used to treat high blood pressure.  Beginning in the summer of 2018, multiple companies announced nationwide (and later global) recalls because these generic drugs were contaminated with dangerous probable carcinogens known as nitrosamines.  This was one of the largest Class I recalls announced by the FDA in history.  Ruben Honik is appointed co-lead counsel, and David Stanoch is appointed liaison counsel, to the nationwide leadership committee steering all valsartan claims nationwide, including those who took these drugs and developed one or more types of cancer (e.g., liver, colon, stomach, rectal, esophageal, pancreatic, prostate, and certain blood cancers), who are seeking refunds for the contaminated drugs they purchased, or who are seeking medical monitoring to screen for cancers that patients may develop in the future.